Journal
CANCER MANAGEMENT AND RESEARCH
Volume 8, Issue -, Pages 77-82Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S93620
Keywords
chemotherapy nausea and vomiting; fosaprepitant; neurokinin inhibitor
Categories
Ask authors/readers for more resources
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance. The dose-limiting side effect of fosaprepitant is an infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. This side effect has been reported with coadministration of anthracycline agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available